384 related articles for article (PubMed ID: 26368542)
1. Comparison of the Prognostic Value of F-18 Pet Metabolic Parameters of Primary Tumors and Regional Lymph Nodes in Patients with Locally Advanced Cervical Cancer Who Are Treated with Concurrent Chemoradiotherapy.
Chong GO; Jeong SY; Park SH; Lee YH; Lee SW; Hong DG; Kim JC; Lee YS; Cho YL
PLoS One; 2015; 10(9):e0137743. PubMed ID: 26368542
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy.
Son SH; Jeong SY; Chong GO; Lee YH; Park SH; Lee CH; Hong CM; Jeong JH; Lee SW; Ahn BC; Lee J
Clin Nucl Med; 2018 Sep; 43(9):e296-e303. PubMed ID: 30036243
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of the Sum of Metabolic Tumor Volume of Primary Tumor and Lymph Nodes Using 18F-FDG PET/CT in Patients With Cervical Cancer.
Hong JH; Min KJ; Lee JK; So KA; Jung US; Kim S; Eo JS
Medicine (Baltimore); 2016 Mar; 95(9):e2992. PubMed ID: 26945420
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy.
Onal C; Guler OC; Reyhan M; Yapar AF
Gynecol Oncol; 2015 Apr; 137(1):40-6. PubMed ID: 25641567
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
Dag Z; Yilmaz B; Dogan AK; Aksan DU; Ozkurt H; Kızılkaya HO; Arslan D
Brachytherapy; 2019; 18(2):154-162. PubMed ID: 30594422
[TBL] [Abstract][Full Text] [Related]
6. (
Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
[TBL] [Abstract][Full Text] [Related]
7. Lymph node standardized uptake values at pre-treatment
Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma.
Calles-Sastre L; Mucientes-Rasilla J; San-Frutos Llorente LM; Royuela A; Garcia-Espantaleón Navas M; Herrero Gámiz S; Pérez-Medina T
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):17-21. PubMed ID: 30366731
[TBL] [Abstract][Full Text] [Related]
9. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.
Herrera FG; Breuneval T; Prior JO; Bourhis J; Ozsahin M
Radiat Oncol; 2016 Mar; 11():43. PubMed ID: 26984385
[TBL] [Abstract][Full Text] [Related]
10. Comparison of FDG PET metabolic tumour volume versus ADC histogram: prognostic value of tumour treatment response and survival in patients with locally advanced uterine cervical cancer.
Ueno Y; Lisbona R; Tamada T; Alaref A; Sugimura K; Reinhold C
Br J Radiol; 2017 Jul; 90(1075):20170035. PubMed ID: 28508679
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of pretreatment and after treatment 18F-FDG PET/CT metabolic parameters in patients with locally advanced squamous cell cervical cancer.
Yilmaz B; Dağ S; Ergul N; Çermik TF
Nucl Med Commun; 2019 Mar; 40(3):219-227. PubMed ID: 30585896
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography.
Yoo J; Choi JY; Moon SH; Bae DS; Park SB; Choe YS; Lee KH; Kim BT
Int J Gynecol Cancer; 2012 Sep; 22(7):1226-33. PubMed ID: 22810970
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of qualitative and quantitative ¹⁸F-FDG PET-CT parameters for predicting survival in recurrent carcinoma of the cervix.
Maharjan S; Sharma P; Patel CD; Sharma DN; Dhull VS; Jain SK; Thulkar S; Malhotra A; Kumar R
Nucl Med Commun; 2013 Aug; 34(8):741-8. PubMed ID: 23676840
[TBL] [Abstract][Full Text] [Related]
14. Tumor total lesion glycolysis and number of positive pelvic lymph nodes on pretreatment positron emission tomography/computed tomography (PET/CT) predict survival in patients with locally advanced cervical cancer.
De Cuypere M; Lovinfosse P; Gennigens C; Hermesse J; Rovira R; Duch J; Goffin F; Hustinx R; Kridelka F
Int J Gynecol Cancer; 2020 Nov; 30(11):1705-1712. PubMed ID: 33033165
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment metabolic tumour volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy.
Guler OC; Torun N; Yildirim BA; Onal C
Br J Radiol; 2018 Apr; 91(1084):20170552. PubMed ID: 29293366
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer.
Hong JH; Jung US; Min KJ; Lee JK; Kim S; Eo JS
Nucl Med Commun; 2016 Aug; 37(8):843-8. PubMed ID: 27058362
[TBL] [Abstract][Full Text] [Related]
17. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma.
Abd El-Hafez YG; Moustafa HM; Khalil HF; Liao CT; Yen TC
Oral Oncol; 2013 Mar; 49(3):261-8. PubMed ID: 23036774
[TBL] [Abstract][Full Text] [Related]
18. The Role of the Metabolic Parameters of
Wang D; Liu X; Wang W; Huo L; Pan Q; Ren X; Zhang F; Hu K
Front Oncol; 2021; 11():698744. PubMed ID: 34490094
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer.
Cima S; Perrone AM; Castellucci P; Macchia G; Buwenge M; Cammelli S; Cilla S; Ferioli M; Ferrandina G; Galuppi A; Salizzoni E; Rubino D; Fanti S; De Iaco P; Morganti AG
Int J Gynecol Cancer; 2018 Mar; 28(3):575-580. PubMed ID: 29372911
[TBL] [Abstract][Full Text] [Related]
20. Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?
Voglimacci M; Gabiache E; Lusque A; Ferron G; Ducassou A; Querleu D; Motton S; Chantalat E; Courbon F; Martinez A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1551-1559. PubMed ID: 30729273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
